Overview
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2006 on request of the sponsor.
On 21 October 2002, orphan designation (EU/3/02/117) was granted by the European Commission to Pharmasan GmbH, Germany, for boswellia serrata resin extract for the treatment of peritumoral oedema derived from brain tumours.
Key facts
Active substance |
Boswellia serrata
|
Intended use |
Treatment of peritumoral oedema derived from brain tumours
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/02/117
|
Date of designation |
21/10/2002
|
Sponsor |
Pharmasan GmbH
Obere Hardtstrasse 18 79114 Freiburg Germany Telephone: +49 761 4909100 Telefax: +49 761 4909 125 E-mail: r.diepold@pharmasan.de |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: